A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Clinical trial NCT06668103 · RECRUITING

Trial details

NCT number: NCT06668103
Sponsor: Abbisko Therapeutics Co, Ltd
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer With EGFR Mutation

Start date: 2024-11-25
Primary completion: 2027-12-30
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.